Hao Huang
  • Education & Experience

    2016-present    Principle Investigator, Peking University, Shenzhen Graduate School
    2015 -2016       Senior Research Scientist (permanent position), Astex Pharmaceuticals, Cambridge, UK
    2011 -2015       Postdoctoral Fellow, Mount Sinai Hospital-Toronto & University of Toronto, Canada (Supervisor: Dr. Frank Sicheri)
    2006-2011        Ph. D in Biochemistry, University of Calgary, Canada (Supervisor: Dr. Hans Vogel)
    2004-2005        M.Sc. in Chemistry, McMaster University, Canada
    1999-2002        M.Sc. in Analytical Chemistry, Tsinghua University 
    1995-1999        B.Sc. in Biology, Sichuan University

  • Awards & Honors

    2017        Bayer-PKU Investigator 

    2014        Canadian Institutes of Health Research (CIHR) postdoctoral fellowship
    2014        Toronto-TD Bank Health Research postdoctoral fellowship
    2008        Alberta Heritage Foundation for Medical Research (AHFMR) Ph.D studentship

  • Research Fields
    The Hao Huang lab aims to discover small molecular anticancer drug leads.  We employ Fragment Based Drug Discovery (FBDD) and structure based drug design to discover inhibitors targeting important proteins in cancer signalling pathways. In the process of discovering novel anticancer drugs, we use integrative approaches of structural biology, chemical biology and computational chemistry. Specifically, we work on the drug discovery targeting the ubiquitin-proteasome system (UPS). Self-motivated students, postdocs and research associates are encouraged to contact me if you are interested in joining our research lab. 
  • Selected Publications
    1.  Huang H, Zeqiraj E, Dong B, Jha BK, Duffy NM, Orlicky S, Thevakumaran N, Talukdar M, Pillon MC, Ceccarelli DF, Wan LC, Juang YC, Mao DY, Gaughan C, Brinton MA, Perelygin AA, Kourinov I, Guarné A, Silverman RH, Sicheri F, Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon induced antiviral activity.  Mol. Cell. 2014; 53, 221-34 (Recommended by F1000:http://f1000.com/prime/718246713)
    2. Huang H*, Ceccarelli DF*, Orlicky S*, St-Cyr DJ, Ziemba A, Garg P, Plamondon S, Auer M, Sidhu S, Marinier A, Kleiger G, Tyers M, Sicheri F, E2 enzyme inhibition by stabilization of a low-affinity interface with ubiquitin. Nat. Chem. Biol. 2014 10, 156-63
    3. Fradet-Turcotte A, Canny MD, Escribano-Díaz C, Orthwein A, Leung CC, Huang H, Landry MC, Kitevski-LeBlanc J, Noordermeer SM, Sicheri F, Durocher D. 53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark. Nature. 2013, 499, 50-54. 
    4. Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T, Huang H, Dunham WH, Fukumura R, Xie G, Gondo Y, Raught B, Gingras AC, Sicheri F, Cordes SP. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis.  Nature. 2013, 498, 318-24
    5. Huang H, Bogstie JN, Vogel HJ, Biophysical and Structural Studies of the Human Calcium- and Integrin-Binding Protein Family: Understanding their Functional Similarities and Differences. Biochem. Cell Biol., 2012, 90, 646-56
    6. Huang H and Vogel HJ, Structural Basis for the Activation of the Cytoplasmic Domain of the Human Platelet Integrin AlphaIIb-beta3 by CIB1. J. Am. Chem. Soc.2012, 134, 3864-72(Highlighted in Science Daily:http://www.sciencedaily.com/releases/2012/03/120319095011.htm)
    7. Huang H, Ishida H, Yamniuk, AP, Vogel HJ, The Solution Structures of Ca2+- CIB1 and Mg2+-CIB1 and their interactions with the Platelet Integrin αIIb Cytoplasmic Domain. J. Biol. Chem., 2011, 286, 17181-92
    8. Huang H, Ishida H, Vogel HJ, The Solution Structure of the Mg2+- form of Soybean Calmodulin Isoform 4 Reveals Unique Features of Plant Calmodulins in Resting Cells. Protein Sci., 2010, 19, 475-85
    9. Huang H, Milojevic J, Melacini G, Analysis and optimization of saturation transfer difference NMR experiments designed to map early self-association events in amyloidogenic peptides. J. Phys. Chem. B., 2008,112, 5795-802
    10. Huang H, Melacini G. High-resolution protein hydration NMR experiments: Probing how protein surfaces interact with water and other non-covalent ligands. Anal. Chim. Acta., 2006, 564, 1-9. 


    Patents

    Tyers M, Sicheri F, Ceccarelli DF, Huang H, et al., Screening methods to identify compounds inhibiting the activity of E2 enzymes by stabilization of non-covalent ubiquitin-E2 complexes and pharmaceutical applications related to E2 inhibitors. Application #: PCT/CA2013/001079;